Tetrabenazine

Drug Profile

Tetrabenazine

Alternative Names: BVF-018; Choreazine Tablets 12.5mg; Nitoman; Xenazina; Xenazine; Xenazine 25

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LifeHealth Limited
  • Developer AFT Pharmaceuticals; Alfresa Pharma Corporation; ApotheekZorg; Cambridge Laboratories; Chiesi Farmaceutici; EUSA Pharma; Lundbeck A/S; Medilink Pharmaceuticals; Orphan Australia; Temmler Pharma; UCB; Valeant Canada
  • Class Antipsychotics; Quinolizines; Small molecules
  • Mechanism of Action Dopamine receptor antagonists; Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease; Gilles de la Tourette's syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Drug-induced dyskinesia; Huntington's disease; Movement disorders
  • Discontinued Gilles de la Tourette's syndrome

Most Recent Events

  • 30 May 2013 Biomarkers information updated
  • 12 Jun 2012 EUSA Pharma has been acquired by Jazz Pharmaceuticals plc
  • 28 Sep 2010 Biovail Corporation merged with Valeant Pharmaceuticals International forming Valeant Pharmaceuticals International
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top